Arletta Taps Veteran CMO to Guide Women's Health Drug Through US Trials

AMSTERDAM, the Netherlands – June 19, 2026

In a move signaling a new phase of strategic ambition, Arletta Pharma Solutions has appointed Dr. Steve van Os, a veteran biopharmaceutical executive, as its Chief Medical Officer. The appointment comes at a critical juncture for the Amsterdam-based company, which is preparing to advance its lead investigational therapy, Lybrido™, into a proposed Phase II clinical study in the United States. The move places a leader with a formidable track record in global drug registration at the helm of a program aimed at one of the most complex and underserved areas of modern medicine: female sexual dysfunction.

Arletta, which rebranded from Freya Pharma Solutions late last year, is focused on developing therapies for Female Sexual Interest/Arousal Disorder (FSIAD) and Hypoactive Sexual Desire Disorder (HSDD). These conditions, which affect millions of women globally, have long been shrouded in social taboo and clinical neglect. By bringing in Dr. van Os, Arletta is making a clear statement about its readiness to navigate the notoriously challenging regulatory pathways and bring a novel on-demand treatment to a market ripe for innovation.

A Strategic Appointment for a Pivotal Moment

Dr. van Os is not a typical hire. His career is distinguished by more than two decades of steering complex therapies through global development, medical affairs, and regulatory negotiations. His most notable achievement came during his tenure at Astellas Pharma, where he was globally accountable for the clinical development and registration of enzalutamide (Xtandi), a blockbuster drug for prostate cancer that achieved registration in over 97 countries. This experience—shepherding a major drug through interactions with agencies like the FDA in the U.S., EMA in Europe, and others—is precisely the expertise Arletta needs as it looks to enter the U.S. market.

“Steve brings the rare combination of strategic development leadership, operational discipline and regulatory depth that we need at exactly this point in Arletta’s evolution,” said Manuel Voll, Chairman of Arletta’s Supervisory Board, in a statement. “As we prepare to open a new chapter with the proposed U.S. Phase II Monarch study for Lybrido™, his track record across global programs, biotech innovation and cross-functional execution will be immensely valuable.”

Dr. van Os’s role will be comprehensive, overseeing medical strategy, clinical development, and regulatory interactions for Lybrido™ in both the United States and Europe. His background also includes CMO roles at Antev Limited and UPyTher, as well as senior positions at women’s health pioneers like Organon and Schering-Plough, giving him a unique blend of large-pharma operational know-how and agile biotech leadership.

The Science of Synchronicity: Reimagining Treatment for FSIAD

At the heart of Arletta’s strategy is Lybrido™, an investigational therapy designed to address the dual nature of female sexual response. Unlike previously approved treatments that target either the mind or the body, Lybrido™ is engineered to synchronize both. It is an on-demand, fixed-dose combination therapy with two components: a sublingual dose of testosterone in an outer coating, designed to increase sexual motivation, and an inner core of sildenafil (the active ingredient in Viagra) with a delayed-release mechanism to enhance physiological arousal a few hours later.

This dual-action approach is a direct response to the limitations of current options and the complexity of FSIAD, a condition that affects an estimated 8% of adult women globally. Low sexual desire is the most common sexual complaint among women, impacting up to 40% at some point in their lives and causing significant personal distress. Yet, the market has been slow to provide effective solutions. The currently available FDA-approved drugs, Addyi (a daily pill) and Vyleesi (an on-demand injection), have been met with mixed results and carry notable side effects.

Arletta’s approach with Lybrido™ is backed by promising clinical data. In March 2026, the company announced positive results from a Phase II Clitoral Doppler Duplex Ultrasound (CDU) study. The study provided objective physiological evidence that Lybrido™ works as intended, showing a greater than 60% average improvement in clitoral blood flow. The high-dose combination achieved statistical significance, a critical milestone that validates the drug's mechanism and de-risks future, larger-scale trials like the upcoming Monarch study.

Navigating a Complex and Evolving Market

The path to approval for any drug targeting female sexual dysfunction is fraught with challenges. The regulatory history is a testament to the high bar set by agencies like the FDA, which has been scrutinized for its cautious approach. The journey of Addyi, which was rejected twice before gaining approval in 2015 with a strict warning about its interaction with alcohol, serves as a cautionary tale for developers in this space. Success requires not only robust science but also an impeccable clinical and regulatory strategy.

This is where Dr. van Os’s appointment becomes particularly meaningful. His experience navigating the intricate demands of global regulatory bodies is a key asset in a field where endpoints can be subjective and safety thresholds are paramount. However, the potential reward is substantial. The global market for female sexual dysfunction treatments was valued at approximately $540 million in 2025 and is projected to more than double to over $1.3 billion by the early 2030s, driven by rising awareness and a cultural shift toward validating women's sexual health as a legitimate medical need.

Arletta is entering a market that is not just growing but maturing. The conversation is shifting from one of normalization to one of active intervention, creating a significant opportunity for a therapy that can demonstrate a clear and compelling benefit-risk profile.

From Oncology to Empowerment: A New Chapter for Arletta

Dr. van Os's transition from a career heavily focused on oncology, particularly prostate cancer, to leading a program in women's sexual health is a compelling narrative in itself. It reflects a broader trend of cross-pollination of expertise within biotech, where proven leaders apply their skills to tackle new and challenging unmet needs. The symbolism is not lost on the company, whose butterfly-inspired branding for both its corporate identity and its Monarch study evokes themes of transformation and freedom.

For Arletta, this new chapter is about more than just clinical trials; it's about contributing to a paradigm shift in how women's health is perceived and treated. In his own words, Dr. van Os seems energized by this mission.

“I am excited to join Arletta at this important stage in its development,” he commented. “Women with FSIAD and HSDD continue to face major unmet medical needs, and I believe Arletta has the scientific foundation and strategic clarity to make a meaningful difference. I look forward to working with the team to advance Lybrido™ through its next stage of development.”